Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors

SAN DIEGO, May 20, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective just prior to the 2016 Annual Meeting of Shareholders. Mr. Mitchell has been a member of the Board of Directors for over thirteen years serving in various capacities on the audit, compensation, and nominating and corporate governance committees.

"Tom has been an integral member of the Board and played an instrumental role in helping build Neurocrine to the company it is today," said Kevin C. Gorman, President and Chief Executive Officer. "We wish him well in retirement, and want to thank him for his years of dedication and advice."

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and valbenazine, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with NBI-98854 (valbenazine) development. Specifically, the risks and uncertainties the Company faces include risks that valbenazine development activities may not be completed on time or at all; risks that valbenazine development activities may be delayed for regulatory or other reasons, may fail to demonstrate that valbenazine is safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that valbenazine regulatory submissions may not occur or be submitted in a timely manner; risks that  valbenazine may not obtain regulatory approval or that the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may make adverse decisions regarding valbenazine; risks that valbenazine may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with the Company's dependence on third parties for development and manufacturing activities related to valbenazine; risks that the Company will be unable to raise additional funding, if required, to complete development of valbenazine; risks and uncertainties relating to competitive products and technological changes that may limit demand for valbenazine; and other risks described in the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2016. Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-the-retirement-of-w-thomas-mitchell-from-the-board-of-directors-300272054.html

SOURCE Neurocrine Biosciences, Inc.

Copyright 2016 PR Newswire